Loading clinical trials...
Loading clinical trials...
Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumumab in Participants With Advanced or Metastatic Solid Tumors
Conditions
Interventions
Nivolumab
Daratumumab
Locations
20
United States
Pacific Shores Medical Group
Long Beach, California, United States
University Of Colorado
Aurora, Colorado, United States
Moffitt Cancer Center
Tampa, Florida, United States
University Of Michigan
Ann Arbor, Michigan, United States
Providence Portland Medical Center
Portland, Oregon, United States
Local Institution
St Leonards, New South Wales, Australia
Start Date
June 15, 2017
Primary Completion Date
July 6, 2020
Completion Date
July 6, 2020
Last Updated
July 23, 2021
NCT04657068
NCT04900818
NCT05004116
NCT06440005
NCT07246954
NCT06242470
Lead Sponsor
Bristol-Myers Squibb
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions